Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

Platelet hyper-aggregability triggered death and disability due to cardiovascular diseases is increasing worldwide and becoming a global concern. Therefore, it is necessary to synthesize newer drugs for the management of platelet aggregation. In this study, we investigated the antiplatelet aggregation activity of a novel series of ferrocenylimine compounds (3-10), N-(3-nitro-2-hydroxylbenzylidene)-3-ferrocenylimine (3), N-(3-bromo-2-hydroxylbenzylidene)-3-ferrocenylimine (4), N-(3-bromo-5-chlorosalicylidene)-3-ferrocenylimine (5), N-(ferrocenylformidene)-3-ferrocenylimine (6), N-(3-nitro-2-hydroxylbenzylidene)-4-ferrocenylimine (7), N-(3-bromo-2-hydroxylbenzylidene)-4-ferrocenylimine (8), N-(3-bromo-5-chlorosalicyl)-4-ferrocenylimine (9), N-(ferrocenylformidene)-4-ferrocenylimine (10) on thrombin- and ADP-induced platelet aggregation. The synthesized ferrocenylimine compounds (3-10) were found to exhibit higher antiplatelet aggregation activity than their precursors, which are 3-ferrocenylaniline (compound 1) and 4-ferrocenylaniline (compound 2). Among the derivatives, compounds 5, 6 and 10 possessed excellent platelet aggregation inhibition against the agonists.